📖 Approx. 7 min
When pursuing a third-party succession (M&A) for a medical corporation or clinic, one of the primary concerns for directors and owners is the market rate and breakdown of brokerage fees paid to advisory firms. Healthcare M&A fees generally follow the “Lehman formula” similar to standard corporate acquisitions. However, calculating the exact amount can become complex due to healthcare-specific valuation factors such as the presence or absence of equity interests, medical fee reimbursement claim rights, and the transfer of liabilities. This article provides an expert breakdown of the healthcare M&A fee structure, estimated success fees, and associated costs that are easily overlooked.
Healthcare M&A Fee Structures and Fundamentals of the Lehman Formula
Healthcare M&A advisory fees are typically calculated using a tiered rate schedule based on transaction value, known as the “Lehman formula.” In this structure, the fee percentage decreases as the transaction size increases, and it is widely adopted by healthcare-specialized brokerage firms and M&A advisory practices.
- Portion of transaction value up to ¥500 million: 5%
- Portion between ¥500 million and ¥1 billion: 4%
- Portion between ¥1 billion and ¥5 billion: 3%
- Portion between ¥5 billion and ¥10 billion: 2%
- Portion exceeding ¥10 billion: 1%
*The above is a standard guideline; rates may vary depending on the advisory firm and contract structure. A minimum fee (minimum advisory fee) is also commonly established.
It is crucial to note that the definition of “transaction value (base price)” varies among M&A advisory firms. There are three primary calculation bases, and the total fee can fluctuate substantially depending on which base is adopted.
Because medical facility successions frequently involve substantial medical equipment leases and long-term real estate loans for hospital buildings, verifying which calculation method is specified in the advisory agreement in advance is critical.
Fee Breakdown and Timing of Payments in Healthcare M&A
Advisory fees incurred during a healthcare M&A transaction generally fall into two categories: pure success-fee models and phased-fee models. Below is a breakdown of common fee components and their payment timings:
A fixed fee charged to conduct initial assessments, create non-name teaser sheets, and initiate prospective buyer sourcing. The typical range is ¥500,000 to ¥2,000,000, though it is ¥0 for firms operating under a pure success-fee model.
A recurring monthly fee (typically ¥100,000 to ¥500,000) for dedicated advisory work. Because prolonged negotiations can make this costly, an increasing number of advisory firms now offer zero monthly retainers.
Paid when both parties execute a basic agreement or letter of intent, typically representing 10%–20% of the estimated success fee (or a fixed fee of ¥1,000,000 to ¥3,000,000). This fee is usually non-refundable even if the deal is terminated prior to closing.
Payable upon execution of the definitive business transfer agreement, adoption of board/member resolutions for director turnover, and completion of fund settlement. Any previously paid interim fees are deducted from the final success fee total.
Healthcare-Specific Succession Schemes and Fee Considerations
Unlike standard corporate share transfers, medical corporation M&A involves unique regulatory procedures and licensing considerations depending on the legal form of the medical entity. These factors directly affect the fee calculation baseline and operational workload.
Medical Corporations with Equity vs. without Equity
For transitional medical corporations (including those with capital contribution limits—”medical corporations with equity”), the equity transfer value is clearly quantifiable, making calculation based on transfer consideration relatively straightforward. However, careful consideration must be given to capital gains taxation (20.315% separate taxation).
Conversely, for “medical corporations without equity” (such as fund-contributed medical corporations), buying and selling equity is legally impermissible. Instead, ownership is effectively transferred through executive retirement severance packages, fund refunds, and the replacement of general members and directors (member turnover scheme). In such transactions, clear contractual terms are essential to establish whether the fee base is the severance amount, the contributed fund balance, or the net asset valuation.
Transfer of Insurance Claims and Facility Standards
In sole proprietorship clinic transfers or medical corporation split-off successions, obtaining a new opening permit and re-applying for designation as an insured healthcare institution (including eligibility for retroactive designation) are pivotal. Maintaining facility standards and settling accounts receivable for medical fees increases the complexity of healthcare due diligence, which may lead to higher minimum advisory fees.
Comparison: Pure Success Fee vs. Upfront & Milestone Fee Models
The choice of fee structure depends on the cash flow and risk tolerance of both sellers and buyers. The table below summarizes the key differences:
| Item | Pure Success Fee Model | Upfront & Milestone Model |
|---|---|---|
| Initial Upfront Cost | ¥0 | Approx. ¥500,000 – ¥2,000,000 |
| Monthly Retainer | ¥0 | Approx. ¥0 – ¥500,000 |
| Risk if Deal Fails | No financial loss | Paid fees are non-refundable |
| Minimum Fee (Guideline) | Approx. ¥5,000,000 – ¥15,000,000 | Approx. ¥3,000,000 – ¥10,000,000 |
| Suitable Medical Facilities | Clinics exploring succession options / entities seeking to minimize initial risk | Large hospitals with high transaction certainty seeking dedicated, rapid execution |
Pure success fee structures eliminate financial loss if a deal is not finalized, making them increasingly popular among private practice clinics and small-to-medium medical corporations facing succession challenges.
Ancillary Expenses and Tax Considerations Beyond Advisory Fees
When planning a healthcare M&A budget, several professional fees, administrative charges, and tax obligations must be factored in alongside brokerage fees.
- Due Diligence (DD) Costs: Primarily borne by the buyer. Retaining specialists for financial, tax, legal, labor, and medical/regulatory DD typically ranges from ¥1,000,000 to ¥5,000,000.
- Administrative Scrivener & Judicial Scrivener Fees: Articles of incorporation amendment approvals, administrator change notifications, board member registrations, real estate title transfers, etc. (Approx. ¥300,000 – ¥1,000,000).
- Real Estate Appraisal Fees: Incurred when obtaining fair market valuations for hospital land and buildings (Approx. ¥500,000 – ¥1,500,000).
- Tax Advisory Costs: Certified tax accountant fees for evaluating the individual business succession tax scheme, enterprise tax exemptions, or preferential tax treatments for continuous medical practice.
On the tax side, preliminary calculations by a certified tax accountant well-versed in medical taxation are essential—not only for equity capital gains tax, but also for corporate deductible limits on executive severance pay and consumption tax treatments (taxable for medical equipment and goodwill transfers; exempt for social insurance medical treatments).
Key Checklist for Selecting a Reliable Healthcare M&A Advisor
Selecting an M&A advisor purely based on low fees can lead to poor matching outcomes and regulatory complications. To choose the right advisory partner, review the following checklist prior to engagement:
✅ Is the firm registered as an “M&A Support Agency” with the Small and Medium Enterprise Agency?
✅ Is the fee calculation base (equity value / enterprise value / total assets) clearly specified in the contract?
✅ Is the minimum success fee proportionate to the scale of your medical facility?
✅ Do they have in-depth knowledge of healthcare regulations (e.g., Regional Medical Care Vision, physician surplus/shortage area restrictions)?
✅ Are dedicated advisors thoroughly familiar with administrative procedures (public health centers, Regional Bureaus of Health and Welfare, etc.)?
Succession of a medical corporation is more than a financial transaction; it must ensure the continuity of local healthcare and protect ongoing employment. Choosing a support partner with fee transparency and deep expertise in healthcare regulatory compliance is the cornerstone of a successful transition.
For medical directors and clinic owners seeking detailed fee estimates for equity transfers, clinic successions, or successor recruitment, please contact the specialized advisors at M&A Medical, a certified M&A Support Agency by the Small and Medium Enterprise Agency.
Consult M&A Medical for Healthcare Succession
M&A Medical is a specialized M&A and business succession advisory service for healthcare institutions. As a registered M&A Support Agency by the Small and Medium Enterprise Agency, we support clinics and medical corporations facing successor shortages with everything from transfer to strategic acquisition under a success-fee structure.
- Initial consultation and preliminary valuation are free of charge
- ¥0 upfront engagement fee and monthly retainers (Success-fee only)
- Strict confidentiality guaranteed (Under non-disclosure agreements)
- Covering all 47 prefectures and all medical specialties across Japan
Whether you want to understand market valuations, address a lack of successors, or explore joining a medical group, please feel free to reach out to us at the earliest stage of your consideration.